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University of Bologna, Bologna, ItalySee Article, pages 978–983Albumin is the most abundant protein in human plasma that is
produced exclusively in the liver. Traditionally, albumin has been
thought of being important in providing plasma with its oncotic
property and therefore its use in clinical practice has been mainly
aimed at promoting plasma volume expansion. The past 10 years
or so has seen an explosion in the knowledge of albumin biology
such that it is now clear that it has multifunctional properties
ranging from provision of oncotic pressure, immune regulation
and endothelial stabilization to being a molecule that works in
the intracellular compartment modifying several key pathophys-
iological mechanisms (reviewed in Garcie-Martinez et al.) [1]. It
has been hypothesized that the pleiotropic effects of albumin in
cirrhosis and its proven effectiveness in spontaneous bacterial
peritonitis, prevention of post paracentesis circulatory dysfunc-
tion, hepatorenal syndrome and hepatic encephalopathy relates
to these functional characteristics rather than simple volume
expansion [1]. Indeed, albumin administration, but not hydroxy-
ethyl starch, improves systemic hemodynamics in patients with
spontaneous bacterial peritonitis by decreasing endothelial acti-
vation [2]. Moreover, in experimental cirrhosis in rats, albumin
exerts a positive cardiac inotropic effect counteracting oxidative
stress- and TNF-a-induced impairment of cardiac contractility
[3]. Given the pathophysiological importance of cirrhotic cardio-
myopathy in hepatorenal syndrome, it is likely that the beneﬁcial
effects of albumin in this setting are mediated, at least in part, by
these mechanisms. The paper in the current issue of the Journal of
Hepatology by Oettl et al. adds to that growing literature by sug-
gesting that albumin may be irreversibly oxidized in advanced
cirrhosis, and this reduction in albumin function predicts mortal-
ity [4].
Albumin is 67 kDa protein and because of its amino acid com-
position it has a negative net charge at pH 7, which makes it sol-
uble and imparts its oncotic properties. From the functionalJournal of Hepatology 20
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classes of functional domains. It has a metal binding domain,
which gives it the property to bind to and remove highly toxic
reactive metal species. Assays, which measure binding of cobalt
to albumin have been developed and the molecule defective in
this function is known as ‘ischemia-modiﬁed albumin (IMA)’.
The second is a group of domains that bind a variety of sub-
stances such as long-chain fatty acids, bilirubin, anions, bile acids,
endotoxin, hormones, and eicosanoids. The function of these
binding domains can be studied using electron paramagnetic res-
onance spectroscopy (EPR), which essentially measures the bind-
ing of and release characteristics of albumin using labeled stearic
acid [1,5]. Studies of the functional capacity of albumin in cir-
rhotic patients using these techniques were described recently.
Albumin functional impairment closely correlated with the
degree of liver insufﬁciency. The IMA/total albumin ratio was sig-
niﬁcantly higher in non-surviving patients with acute-on-chronic
liver failure (ACLF) leading to the concept of ‘effective albumin
concentration’, which is dependent upon the functional charac-
teristics of albumin rather than its quantity. Importantly, the
investigators showed that albumin dialysis did not restore the
functional ability of the native molecule suggesting that albumin
in liver failure may be irreversibly destroyed [5]. The third major
function of albumin is its thiol function, which is imparted by a
free cysteine molecule. It is this property that was the main focus
of the article by Oettl et al. [4].
The free cysteine (Cys-34) residue provides a single free
redox-active thiol (-SH). This is capable of reducing oxidative
stress through thiolation, nitrosylation, and oxidation. In healthy
individuals, albumin exists mostly in a reduced form (with a free
thiol). This is referred to as mercaptoalbumin (HMA). A small pro-
portion of albumin exists as mixed disulﬁde compounds known
as non-mercaptalbumin 1 (HNA1), representing a molecule that
has lost its anti-oxidant property but can be returned to the
HMA form using a reducing agent. In health, a tiny fraction is
found in a highly oxidized form with cysteine 34 (as sulﬁnic or
sulfonic acid) known as non-mercaptalbumin 2 (HMA2). It is
the sulfonic form that is thought to constitute an irreversibly
damaged albumin [1,6]. These three different fractions of albu-
min can be isolated and quantiﬁed by high performance liquid13 vol. 59 j 918–920
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Fig. 1. Schematic representation of the albumin molecule illustrating the main binding domains. Each site/domain is devoted to speciﬁc binding functions; the main
ligands are also concisely reported. Cys-34: free cysteine in position 34; N-terminal: aminoterminus; C-terminal: carbon terminal.
JOURNAL OF HEPATOLOGYchromatography (HPLC). During aging [7] and different diseases,
such as end-stage kidney disease [8] and liver failure [6], the frac-
tions of the oxidized forms are increased. The paper by Oettl et al.
extends this observation and shows for the ﬁrst time that the
proportion of HNA2 measured in the plasma of patients with
advanced cirrhosis may predict mortality [4].
The authors prospectively studied 67 patients who were
admitted to the hospital with acute decompensation of cirrhosis
of whom 18 patients were in the intensive care unit. In addition
to the clinical parameters, they measured albumin function, spe-
ciﬁcally, HMA, HNA1, and HNA2 using HPLC, i.e., looking at the
free cysteine status and they also measured the binding charac-
teristics of albumin to danylsarcosine, which looks at the func-
tional activity of binding site 2 using HPLC as well. They found
that the concentration of both oxidized forms were signiﬁcantly
increased in the cirrhotic patients and the value of HNA2, in par-
ticular correlated closely with the MELD score, bilirubin, INR, and
CRP, conﬁrming that the values were reﬂected by the severity of
liver disease and associated inﬂammation, both of which have
been identiﬁed as predictors of ACLF [9,10]. Therefore, it was
not surprising and important that they found a high predictive
ability of HNA2 in determining 30- and 90-day mortality. In fact,
the prediction of 30-day mortality was possibly higher than
MELD score. A cut-off of 12% was considered optimal and identi-
ﬁed a cohort with a very low survival rate. They observed a cor-
relation between this and danylsarcosine binding which may
suggest that the structural change due to oxidation of albuminJournal of Hepatology 201may have non-speciﬁc effects on other functional characteristics
of albumin. They then validated these data in a second cohort of
40 similar patients from Innsbruck. Finally, in a small sample of 3
patients, they extended their ﬁndings using mass spectrometry
and conﬁrmed that the HNA2 fraction represented an irreversible
damage to albumin as the modiﬁcation of the Cys-34 was in the
sulfonic acid form [4]. The data from this study signiﬁcantly adds
to the weight of the argument that albumin dysfunction is likely
to be pathophysiologically important [1,4]. It would be useful to
know in a larger cohort of patients whether HNA2 is a surrogate
marker of ACLF or independent of it and whether changes in its
concentration occur in the patients who deteriorate in the hospi-
tal (Fig. 1).
These data provide a possible explanation why the current
albumin dialysis systems, such as the molecular adsorbents recir-
culating system (MARS) or Prometheus, have not been shown to
improve the survival of patients with liver failure [11,12]. The
concept these devices are based upon is the potential reversibility
of albumin dysfunction in liver failure as the damaged albumin is
not removed and remains in the circulation. In MARS, the
patient’s blood is dialysed against albumin across a membrane
with a 55 kDa cut-off [11]. Therefore, if the patient’s albumin is
irreversibly destroyed, it cannot be regenerated. In Prometheus,
the patient’s is simply cleaned by ﬁlters in the secondary circuit
[12]. An irreversibly destroyed albumin will therefore not be
regenerated. By contrast, plasma exchange, which allows removal
of the damaged molecule, has been recently shown to improve3 vol. 59 j 918–920 919
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survival in acute liver failure patients but is limited by non-selec-
tivity [13]. Based upon these data, newer devices that address
albumin exchange are in development [14].
The data in this study generates numerous new questions. It is
not clear whether the increased concentration of HNA2 detected
in the patients who will die is only a marker or whether this may
actually be harmful to cell function. The mechanism of formation
of HNA2 remains to be deﬁned. In the test tube, HNA2 can be
generated by the addition of hydrogen peroxide. Therefore, it is
likely that inﬂammation and the associated oxidative stress can
produce HNA2 in vivo. An alternative question is whether the
stressed hepatocyte is producing a functionally damaged albumin
due to cellular stress leading to alterations in the folding of the
albumin molecule. This will need to be investigated in future
studies. The authors have clearly identiﬁed a potential biomarker.
Larger numbers of patients will be required to conﬁrm their data
and it will be important to simultaneously study all the known
albumin functions to tease out whether more than one function
will further improve its prognostic ability. In order for this to
happen, a simpler bedside test will need to be developed. Finally,
it will be important to answer whether the concentration of
HNA2 changes with either deterioration or improvement of liver
function and whether instead of aiming at a target concentration
of albumin, one should be aiming at a ‘functional concentration’
of albumin, i.e., a goal directed approach [1].
In conclusion, on-going research in the ﬁeld of albumin biol-
ogy in liver failure has opened up new translational possibilities
which will impact on ﬁnding new indications for albumin use,
functional characterization to deﬁne ‘effective albumin concen-
tration’, and the use of these concepts to design new albumin
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